News Feed

By Will Boggs MD

NEW YORK (Reuters Health) - Risankizumab, a monoclonal antibody that binds to the p19 subunit of interleukin-23, is effective for treating moderate-to-severe plaque psoriasis, according to results from two phase 3 trials.

By Reuters Staff

NEW YORK (Reuters Health) - Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn's disease (CD), according to data from company-sponsored clinical trials.

By Reuters Staff

NEW YORK (Reuters Health) - Adolescents with acne are more likely to engage in self-injurious behavior than their clear-skinned peers, a small study from Turkey hints.

By Lisa Rapaport

(Reuters Health) - The recombinant zoster vaccine Shingrix prevents shingles, and if people do contract the virus, it reduces the severity of illness, two company-funded studies suggest.

By Anne Harding

NEW YORK (Reuters Health) - Cutaneous adverse reactions to programmed cell death protein 1 (PD-1) inhibitors can occur months after treatment initiation, and can also arise after patients stop taking the drugs, new research shows.

By Marilynn Larkin

NEW YORK (Reuters Health) - Expression of major histocompatibility complex (MHC) class I and class II proteins may help predict a patient's response to melanoma immunotherapy, researchers have found.

By Scott Baltic

By Gene Emery

By Will Boggs MD

NEW YORK (Reuters Health) - Combined systemic and intratumoral human papillomavirus (HPV) vaccine administration resulted in complete regression of multiple cutaneous basaloid squamous cell carcinomas, according to a case report.

By Anne Harding